Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow EVO by emailGet an email when EVO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EVO, unsubscribe in one click. Privacy
📣 What EVO Says Is Next
by 2028 · “MID-TERM FRAMEWORK 2026 - 2030 4 Group revenues are expected to grow to > €1 billion (8-12 % CAGR) 4 Adjusted EBITDA margin is expected to reach 20% by 2028 and exceed that level by 2030 3 INTERIM STATEMENT 3M 2026 FINANCIAL HIGHLIGHTS The following table provides an overview of the financial performance in the first three months of 2026 compared to the same period in 2025.”
Company press release, May 6, 2026 · SEC filing
by end of 2027 · “Horizon operating model transformation : Initiated with footprint reduction to 10 sites, establishment of Centers of Excellence and commercial leadership development; expected run-rate cost savings of ~€75 million by end of 2027 with first financial benefit visible 2H 2026”
Company press release, Apr 8, 2026 · SEC filing
fourth quarter · “For full-year 2025, Evotec expects results to fall within its previously communicated guidance ranges: · Group revenues of approximately €788 million at the high end of the €760-800 million guidance (€811 million at constant exchange rates (CER)) · Adjusted Group EBITDA of approximately €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report final fourth quarter and full-year 2025 results on April 8, 2026.”
Company press release, Mar 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full EVO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EVO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.